NCT01460940 - A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 13, 2011

Primary Completion Date

November 16, 2016

Study Completion Date

November 16, 2016

Conditions

Adult Lymphocyte Depletion Hodgkin LymphomaAdult Lymphocyte Predominant Hodgkin LymphomaAdult Mixed Cellularity Hodgkin LymphomaAdult Nodular Lymphocyte Predominant Hodgkin LymphomaAdult Nodular Sclerosis Hodgkin LymphomaRecurrent Adult Hodgkin Lymphoma

Interventions

DRUG

panobinostat

Administered orally Monday, Wednesday, Friday of every week for 4 weeks. A cycle is define as 28 days.

DRUG

lenalidomide

Lenalidomide will be administered orally daily on days 1-21. Lenalidomide will not be given on days 22-28. A cycle is define as 28 days.

Trial Locations (2)

43210

The Ohio State University Medical Center, Columbus

63110

Washington University, St Louis